Gesine Bug, Andreas Burchert, Eva-Maria Wagner, Nicolaus Kröger, Tobias Berg, Saskia Güller, Stephan Klaus Metzelder, Andrea Wolf, Sabine Hünecke, Peter Bader, Johannes Schetelig, Hubert Serve, Oliver Gerhard Ottmann
- Maintenance therapy after allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) is conceptually attractive to prevent relapse, but has been hampered by the limited number of suitable anti-leukemic agents. The deacetylase inhibitor (DACi) panobinostat demonstrated moderate anti-leukemic activity in a small subset of patients with advanced AML and high-risk MDS in phase I/II trials.1, 2 It also displays immunomodulatory activity3 that may enhance leukemia-specific cytotoxicity4 and mitigate graft versus host disease (GvHD), but conversely could impair T- and NK cell function.5, 6 We conducted this open-label, multi-center phase I/II trial (NCT01451268) to assess the feasibility and preliminary efficacy of prolonged prophylactic administration of panobinostat after HSCT for AML or MDS. The study protocol was approved by an independent ethics committee and conducted in compliance with the Declaration of Helsinki. All patients provided written informed consent. ...
MetadatenAuthor: | Gesine Bug, Andreas BurchertORCiDGND, Eva-Maria Wagner, Nicolaus Kröger, Tobias Berg, Saskia Güller, Stephan Klaus Metzelder, Andrea Wolf, Sabine HüneckeGND, Peter BaderORCiDGND, Johannes Schetelig, Hubert ServeORCiDGND, Oliver Gerhard Ottmann |
---|
URN: | urn:nbn:de:hebis:30:3-457895 |
---|
DOI: | https://doi.org/10.1038/leu.2017.242 |
---|
ISSN: | 1476-5551 |
---|
ISSN: | 0887-6924 |
---|
Pubmed Id: | https://pubmed.ncbi.nlm.nih.gov/28751769 |
---|
Parent Title (English): | Leukemia |
---|
Publisher: | Springer Nature |
---|
Place of publication: | London |
---|
Document Type: | Article |
---|
Language: | English |
---|
Year of Completion: | 2017 |
---|
Date of first Publication: | 2017/07/28 |
---|
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Release Date: | 2018/03/01 |
---|
Tag: | Acute myeloid leukaemia; Molecularly targeted therapy; Myelodysplastic syndrome; Phase I trials; Stem-cell therapies |
---|
Volume: | 31 |
---|
Issue: | 11 |
---|
Page Number: | 3 |
---|
First Page: | 2523 |
---|
Last Page: | 2525 |
---|
Note: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
---|
HeBIS-PPN: | 432026479 |
---|
Institutes: | Medizin / Medizin |
---|
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Licence (German): | Creative Commons - Namensnennung 4.0 |
---|